Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

News provided by

Jan 31, 2012, 06:44 ET

NEW YORK, Jan. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

http://www.reportlinker.com/p0766036/Immunomodulators-Market-to-2017---Immunosuppressant-Antibodies-to-Replace-Antimetabolites-as-the-Highest-Value-Sector-by-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

Summary Europe

GBI Research analysis estimated the global immunomodulators market to be valued at $145.9 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 13.1% between 2002 and 2010. The market is forecast to grow at a CAGR of 8.6% between 2010 and 2017, to reach $259.3 billion in 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and in–house analysis by the GBI Research team of experts.

GBI Research analysis found the R&D pipeline for the immunomodulators market to be strong. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that R&D activity for immunomodulators will remain active for at least next four to five years.

Scope Europe

- Annualized market data for the immunomodulators market from 2002 to 2010, with forecasts to 2017.

- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes

- Key drivers and restraints that have had significant impact on the market.

- Competitive landscape of the global immunomodulators market including benchmarking of the top companies. The key companies studied in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Bristol-Myers Squibb, Eli Lilly.

Reasons to buy

- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of the top competitors.

- Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first–in-class molecules with improved efficacy and safety profiles.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 132 Immunomodulators Market to 2017 - Market Introduction 172.1 GBI Research Report Guidance 173 Immunomodulators Market to 2017 - Market Characterization 193.1 Classification 193.2 Drivers and Barriers 203.3 Global Immunomodulators Market Drivers 203.4 Global Immunomodulators Market Restraints 213.5 Unmet Needs 223.6 Revenue Forecast - Global 234 Immunomodulators Market to 2017 - Geographical Landscape 274.1 The US 274.2 Europe 284.3 ROW 295 Immunomodulators Market to 2017 - Immunosuppressants 305.1 Introduction 305.2 Drug Classes 305.3 Applications 305.4 Global Market Size 316 Immunosuppressants - Antibodies 326.1 Introduction 326.2 Prescription Population 336.3 Annual Cost of Therapy 376.4 Revenue 426.5 Pipeline Molecules 467 Immunosuppressants - Interferon Beta 507.1 Introduction 507.2 Prescription Population 507.3 Annual Cost of Therapy 557.4 Revenue 597.5 Pipeline Molecules 638 Immunosuppressants - Glucocorticoids 658.1 Introduction 658.2 Therapeutic Indications 658.3 Immunological Mode of Action 658.4 Prescription Population 678.5 Annual Cost of Therapy 718.6 Revenue 758.7 Pipeline Molecules 799 Immunosuppressants - Calcineurin Inhibitors 1049.1 Introduction 1049.2 Prescription Population 1049.3 Annual Cost of Therapy 1099.4 Revenue 1139.5 Pipeline Molecules 11710 Immunosuppressants - Antimetabolites 13710.1 Introduction 13710.2 Prescription Population 13710.3 Annual Cost of Therapy 14210.4 Revenue 14610.5 Pipeline Molecules 15011 Immunomodulators Market to 2017 - Immunostimulants 18911.1 Introduction 18911.2 Drug Classes 18911.3 Applications 18911.4 Global Market Size 19012 Immunostimulants - Vaccines, Active Immunity 19112.1 Introduction 19112.2 Target Population 19212.3 Revenue 19312.4 Pipeline Molecules 19813 Immunostimulants: Antibodies - Passive Immunity 21013.1 Introduction 21013.2 Prescription Population 21013.3 Annual Cost of Therapy 21513.4 Revenue 21913.5 Pipeline Molecules 22314 Immunostimulants: Interferon Alpha - Passive Immunity 23514.1 Introduction 23514.2 Prescription Population 23614.3 Annual Cost of Therapy 24014.4 Revenue 24414.5 Pipeline Molecules 24815 Immunomodulators Market to 2017 - Competitive Landscape 25715.1 Market Share Analysis 25715.2 Hoffmann-La Roche Ltd Roche 25815.3 Amgen Inc 25915.4 Abbott Laboratories 26015.5 Johnson & Johnson 26115.6 Novartis AG 26215.7 Biogen Idec 26415.8 Merck & Co Inc 26515.9 Bristol Myers Squibb Company 26615.10 Eli Lilly and Company 26716 Immunomodulators Market to 2017 - Strategic Consolidations 26916.1 M&A Deals by Type 26916.2 M&A Landscape 27016.3 Major Deals 27216.4 Licensing Deals 27316.5 Major Deals 27516.6 Partnership Deals 27616.7 Major Deals 27917 Immunomodulators Market to 2017 - Appendix 28017.1 Market Definitions 28017.2 Abbreviations 28017.3 Research Methodology 28117.4 Therapeutic Landscape 28217.5 Geographical Landscape 28517.6 Pipeline Analysis 28517.7 Competitive Landscape 28517.8 Contact Us 28517.9 Disclaimer 28517.10 Sources 286

1.1 List of Tables

Table 1: Immunomodulators Market to 2017, Global, Revenue ($bn), 2002-2010 27Table 2: Immunomodulators Market to 2017, Global, Revenue Forecasts ($bn), 2010-2017 27Table 3: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2002-2010 29Table 4: Immunomodulators Market to 2017, Global, Annual Cost of Therapy ($), 2010-2017 29Table 5: Immunomodulators Market to 2017, Global, Prescription Population (million), 2002-2010 30Table 6: Immunomodulators Market to 2017, Global, Prescription Population (million), 2010-2017 30Table 7: Immunomodulators Market to 2017, The US, Revenue ($bn), 2002-2010 31Table 8: Immunomodulators Market to 2017, The US, Revenue Forecasts (bn), 2010-2017 31Table 9: Immunomodulators Market to 2017, Europe, Revenue ($bn), 2002-2010 32Table 10: Immunomodulators Market to 2017, Europe, Revenue Forecasts ($bn), 2010-2017 32Table 11: Immunomodulators Market to 2017, ROW, Revenue ($bn), 2002-2010 33Table 12: Immunomodulators Market to 2017, ROW, Revenue Forecasts ($bn), 2010-2017 33Table 13: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue ($bn), 2002-2010 35Table 14: Immunomodulators Market to 2017, Immunosuppressants, Global, Revenue Forecasts ($bn), 2010-2017 35Table 15: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2002-2010 37Table 16: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Prescription Population (million), 2010-2017 37Table 17: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2002-2010 38Table 18: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Prescription Population (million), 2010-2017 38Table 19: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2002-2010 39Table 20: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Prescription Population (million), 2010-2017 39Table 21: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2002-2010 40Table 22: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Prescription Population (million), 2010-2017 40Table 23: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2010 41Table 24: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Annual Cost of Therapy ($), 2010-2017 42Table 25: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2010 42Table 26: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Annual Cost of Therapy ($), 2010-2017 43Table 27: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2010 44Table 28: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Annual Cost of Therapy ($), 2010-2017 44Table 29: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2010 45Table 30: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Annual Cost of Therapy ($), 2010-2017 45Table 31: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue ($bn), 2002-2010 46Table 32: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Global, Revenue Forecasts ($bn), 2010-2017 46Table 33: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue ($bn), 2002-2010 47Table 34: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, The US, Revenue Forecasts ($bn), 2010-2017 48Table 35: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue ($bn), 2002-2010 48Table 36: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Europe, Revenue Forecasts ($bn), 2010-2017 49Table 37: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue ($bn), 2002-2010 49Table 38: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, ROW, Revenue Forecasts ($bn), 2010-2017 50Table 39: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase III, 2011 50Table 40: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase II, 2011 51Table 41: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Phase I, 2011 52Table 42: Immunomodulators Market to 2017, Immunosuppressants, Antibodies, Pipeline Molecules, Preclinical/Discovery Phase, 2011 52Table 43: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2002-2010 55Table 44: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Prescription Population (million), 2010-2017 55Table 45: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2002-2010 56Table 46: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Prescription Population, 2010-2017 56Table 47: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2002-2010 57Table 48: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Prescription Population, 2010-2017 57Table 49: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2002-2010 58Table 50: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Prescription Population, 2010-2017 58Table 51: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2002-2010 59Table 52: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Annual Cost of Therapy ($), 2010-2017 59Table 53: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2002-2010 60Table 54: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US Annual Cost of Therapy ($), 2010-2017 60Table 55: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2002-2010 61Table 56: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Annual Cost of Therapy ($), 2010-2017 61Table 57: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2002-2010 62Table 58: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Annual Cost of Therapy ($), 2010-2017 62Table 59: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue ($bn), 2002-2010 63Table 60: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Global, Revenue Forecasts ($bn), 2010-2017 63Table 61: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue ($bn), 2002-2010 64Table 62: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, The US, Revenue Forecasts ($bn), 2010-2017 64Table 63: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue ($bn), 2002-2010 65Table 64: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Europe, Revenue Forecasts ($bn), 2010-2017 65Table 65: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue ($bn), 2002-2010 66Table 66: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, ROW, Revenue Forecasts ($bn), 2010-2017 66Table 67: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase III, 2011 67Table 68: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase II, 2011 67Table 69: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Phase I, 2011 67Table 70: Immunomodulators Market to 2017, Immunosuppressants, Interferon Beta, Pipeline Molecules, Preclinical/Discovery Phase, 2011 68Table 71: Immunomodulators Market to 2017, Comparative Glucocorticoid Potency, 2011 70Table 72: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2002-2010 71Table 73: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Prescription Population (million), 2010-2017 71Table 74: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2002-2010 72Table 75: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Prescription Population (million), 2010-2017 73Table 76: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2002-2010 73Table 77: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Prescription Population (million), 2010-2017 74Table 78: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2002-2010 74Table 79: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Prescription Population (million), 2010-2017 75Table 80: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2002-2010 75Table 81: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Annual Cost of Therapy ($), 2010-2017 76Table 82: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2002-2010 76Table 83: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Annual Cost of Therapy ($), 2010-2017 76Table 84: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2002-2010 77Table 85: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Annual Cost of Therapy ($), 2010-2017 77Table 86: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2002-2010 78Table 87: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Annual Cost of Therapy ($), 2010-2017 78Table 88: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue ($bn), 2002-2010 79Table 89: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Global, Revenue Forecasts ($bn), 2010-2017 79Table 90: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue ($bn), 2002-2010 80Table 91: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, The US, Revenue Forecasts ($bn), 2010-2017 81Table 92: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue ($bn), 2002-2010 81Table 93: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Europe, Revenue Forecasts ($bn), 2010-2017 81Table 94: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue ($bn), 2002-2010 82Table 95: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, ROW, Revenue Forecasts ($bn), 2010-2017 82Table 96: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase III, 2011 83Table 97: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase II, 2011 90Table 98: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Phase I, 2011 106Table 99: Immunomodulators Market to 2017, Immunosuppressants, Glucocorticoids, Pipeline Molecules, Preclinical/Discovery Phase, 2011 107Table 100: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2002-2010 109Table 101: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Prescription Population, 2010-2017 109Table 102: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2002-2010 110Table 103: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Prescription Population, 2010-2017 110Table 104: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2002-2010 111Table 105: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Prescription Population, 2010-2017 111Table 106: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2002-2010 112Table 107: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Prescription Population, 2010-2017 112Table 108: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2002-2010 113Table 109: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Annual Cost of Therapy ($), 2010-2017 113Table 110: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2002-2010 114Table 111: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Annual Cost of Therapy ($), 2010-2017 114Table 112: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2002-2010 115Table 113: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Annual Cost of Therapy ($), 2010-2017 115Table 114: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2002-2010 116Table 115: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Annual Cost of Therapy ($), 2010-2017 116Table 116: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue ($bn), 2002-2010 117Table 117: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Global, Revenue Forecasts ($bn), 2010-2017 117Table 118: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue ($bn), 2002-2010 118Table 119: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, The US, Revenue Forecasts ($bn), 2010-2017 118Table 120: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue ($bn), 2002-2010 119Table 121: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Europe, Revenue Forecasts ($bn), 2010-2017 119Table 122: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue ($bn), 2002-2010 120Table 123: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, ROW, Revenue Forecasts ($bn), 2010-2017 120Table 124: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase III, 2011 121Table 125: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase II, 2011 122Table 126: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Phase I, 2011 137Table 127: Immunomodulators Market to 2017, Immunosuppressants, Calcineurin Inhibitors, Pipeline Analysis, Preclinical/Discovery Phase, 2011 140Table 128: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2002-2010 142Table 129: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Prescription Population (million), 2010-2017 142Table 130: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2002-2010 143Table 131: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Prescription Population (million), 2010-2017 143Table 132: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2002-2010 144Table 133: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Prescription Population (million), 2010-2017 144Table 134: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2002-2010 145Table 135: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Prescription Population (million), 2010-2017 145Table 136: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2002-2010 146Table 137: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Annual Cost of Therapy ($), 2010-2017 146Table 138: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2002-2010 147Table 139: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Annual Cost of Therapy ($), 2010-2017 147Table 140: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2002-2010 148Table 141: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Annual Cost of Therapy ($), 2010-2017 148Table 142: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2002-2010 149Table 143: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Annual Cost of Therapy ($), 2010-2017 149Table 144: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue ($bn), 2002-2010 150Table 145: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Global, Revenue Forecasts ($bn), 2010-2017 150Table 146: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue ($bn), 2002-2010 151Table 147: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, The US, Revenue Forecasts ($bn), 2010-2017 151Table 148: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue ($bn), 2002-2010 152Table 149: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, Europe, Revenue Forecasts ($bn), 2010-2017 152Table 150: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue ($bn), 2002-2010 153Table 151: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites, ROW, Revenue Forecasts ($bn), 2010-2017 153Table 152: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase III, 2011 154Table 153: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase II, 2011 160Table 154: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Phase I, 2011 179Table 155: Immunomodulators Market to 2017, Immunosuppressants, Antimetabolites Pipeline Molecules, Preclinical/Discovery Phase, 2011 187Table 156: Immunomodulators Market to 2017, Immunostimulants, Revenue ($bn), 2002-2010 194Table 157: Immunomodulators Market to 2017, Immunostimulants, Revenue Forecasts ($bn), 2010-2017 194Table 158: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Vaccine Preventable Disease, 2010 195Table 159: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population ('000), 2002-2010 196Table 160: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Target Pediatric and Adult Population ('000), 2010-2017 197Table 161: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue ($bn), 2002-2010 198Table 162: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Global, Revenue Forecasts ($bn), 2010-2017 198Table 163: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue ($bn), 2002-2010 199Table 164: Immunomodulators Market to 2017, Immunostimulants, Vaccines, The US, Revenue Forecasts ($bn), 2010-2017 199Table 165: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue ($bn), 2002-2010 200Table 166: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Europe, Revenue Forecasts ($bn), 2010-2017 200Table 167: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue ($bn), 2002-2010 202Table 168: Immunomodulators Market to 2017, Immunostimulants, Vaccines, ROW, Revenue Forecasts ($bn), 2010-2017 202Table 169: Immunomodulators Market to 2017, Immunostimulants, Vaccines, NDA Filed Molecules, 2011 202Table 170: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase III, 2011 203Table 171: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase II, 2011 206Table 172: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Phase I, 2011 209Table 173: Immunomodulators Market to 2017, Immunostimulants, Vaccines, Pipeline Molecules, Preclinical/Discovery Phase, 2011 210Table 174: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2002-2010 215Table 175: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Prescription Population (million), 2010-2017 215Table 176: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2002-2010 216Table 177: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Prescription Population (million), 2010-2017 216Table 178: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2002-2010 217Table 179: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Prescription Population (million), 2010-2017 217Table 180: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2002-2010 218Table 181: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Prescription Population (million), 2010-2017 218Table 182: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2002-2010 219Table 183: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Annual Cost of Therapy ($), 2010-2017 219Table 184: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2002-2010 220Table 185: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Annual Cost of Therapy ($), 2010-2017 220Table 186: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2002-2010 221Table 187: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Annual Cost of Therapy ($), 2010-2017 221Table 188: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2002-2010 222Table 189: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Annual Cost of Therapy ($), 2010-2017 222Table 190: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue ($bn), 2002-2010 223Table 191: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Global, Revenue Forecasts ($bn), 2010-2017 223Table 192: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue ($bn), 2002-2010 224Table 193: Immunomodulators Market to 2017, Immunostimulants, Antibodies, The US, Revenue Forecasts ($bn), 2010-2017 225Table 194: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue ($bn), 2002-2010 225Table 195: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Europe, Revenue Forecasts ($bn), 2010-2017 225Table 196: Immunomodulators Market to 2017, Immunostimulants, I Antibodies, ROW, Revenue ($bn), 2002-2010 226Table 197: Immunomodulators Market to 2017, Immunostimulants, Antibodies, ROW, Revenue Forecasts ($bn), 2010-2017 226Table 198: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, NDA Filed, 2011 227Table 199: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase III, 2011 227Table 200: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase II, 2011 229Table 201: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Phase I, 2011 235Table 202: Immunomodulators Market to 2017, Immunostimulants, Antibodies, Pipeline Molecules, Preclinical/Discovery Phase, 2011 237Table 203: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Pharmaceutical Forms of Interferons, 2011 239Table 204: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2002-2010 240Table 205: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Prescription Population, 2010-2017 240Table 206: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2002-2010 241Table 207: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Prescription Population, 2010-2017 242Table 208: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2002-2010 242Table 209: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Prescription Population, 2010-2017 243Table 210: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue ($bn), 2002-2010 243Table 211: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($bn), 2010-2017 244Table 212: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2002-2010 244Table 213: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Annual Cost of Therapy ($), 2010-2017 245Table 214: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2002-2010 245Table 215: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Annual Cost of Therapy ($), 2010-2017 246Table 216: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2002-2010 246Table 217: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Annual Cost of Therapy ($), 2010-2017 247Table 218: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2002-2010 247Table 219: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Annual Cost of Therapy ($), 2010-2017 248Table 220: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue ($bn), 2002-2010 248Table 221: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Global, Revenue Forecasts ($bn), 2010-2017 249Table 222: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue ($bn), 2002-2010 249Table 223: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, The US, Revenue Forecasts ($bn), 2010-2017 249Table 224: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue ($bn), 2002-2010 250Table 225: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Europe, Revenue Forecasts ($bn), 2010-2017 250Table 226: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue ($m), 2002-2010 251Table 227: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, ROW, Revenue Forecasts ($m), 2010-2017 251Table 228: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase III, 2011 252Table 229: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase II, 2011 254Table 230: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Phase I, 2011 259Table 231: Immunomodulators Market to 2017, Immunostimulants, Interferon Alpha, Pipeline Molecules, Preclinical/Discovery Phase, 2011 260Table 232: Immunomodulators Market to 2017, Roche, Marketed Products, Sales ($m), 2010 262Table 233: Immunomodulators Market to 2017, Amgen Inc, Marketed Products, Sales ($m), 2010 263Table 234: Immunomodulators Market to 2017, Abbott Laboratories, Marketed Products, Sales ($m), 2010 264Table 235: Immunomodulators Market to 2017, Johnson & Johnson, Marketed Products, Sales ($m), 2010 265Table 236: Immunomodulators Market to 2017, Novartis AG, Marketed Products, Sales ($m) 2010 267Table 237: Immunomodulators Market to 2017, Biogen Idec, Marketed Products, Sales ($m), 2010 268Table 238: Immunomodulators Market to 2017, Merck & Co Inc, Marketed Products, Sales ($m), 2010 269Table 239: Immunomodulators Market to 2017, Bristol-Myers Squibb Company, Marketed Products, Sales ($m), 2010 270Table 240: Immunomodulators Market to 2017, Eli Lilly and Company, Marketed Products, Sales ($m), 2010 271Table 241: Immunomodulators Market to 2017, Global, Strategic Consolidations, M&A by Year, 2010-2011 274Table 242: Immunomodulators Market to 2017, Global, Strategic Consolidations, Top Five M&A Deals by Value, 2010-2011 276Table 243: Immunomodulators Market to 2017, Global, St